PCSK9抑制剂相关眼部疾病:药物警戒不均衡分析
PCSK9抑制剂与泪液增加、季节性过敏和眼部手术的报告信号升高相关,依洛尤单抗与阿利西尤单抗间无差异。敏感性分析显示泪液增加信号在排除联合其他降脂药后消失,多数事件发生于首次给药30天内,多见于女性和65岁以上人群。
要点
- PCSK9抑制剂与泪液增加、季节性过敏和眼部手术的报告信号升高相关。
- 依洛尤单抗与阿利西尤单抗之间眼部不良事件报告无差异。
- 泪液增加信号在排除联合其他降脂药后消失,提示可能受混杂影响。
核心结论
- PCSK9抑制剂可能与美国FDA不良事件报告系统中泪液增加、季节性过敏和眼部手术的报告信号升高相关。
- 依洛尤单抗与阿利西尤单抗之间眼部不良事件报告无差异。
研究设计与样本
- 基于FAERS(2004年1月至2021年12月)对PCSK9抑制剂进行不均衡分析。
- 使用信息成分(IC)和报告比值比(ROR)评估关联,并比较依洛尤单抗与阿利西尤单抗的ROR差异。
- 进行多种敏感性分析评估结果稳健性。
主要发现
- 泪液增加:IC 0.27(95%CI 0.02-0.45),ROR 1.21(95%CI 1.04-1.40)。
- 季节性过敏:IC 0.39(95%CI 0.04-0.64),ROR 1.32(95%CI 1.07-1.62)。
- 眼部手术:IC 0.66(95%CI 0.04-1.10),ROR 1.60(95%CI 1.11-2.30)。
- 敏感性分析显示,排除联合其他降脂药的病例后,泪液增加的不均衡信号消失。
- 除眼部手术外,多数不良事件发生于首次给药30天内,3种眼部不良事件多见于女性和65岁以上人群。
临床怎么用
- 临床使用PCSK9抑制剂时应关注眼部不良事件,尤其是女性和65岁以上人群。
- 首次给药后30天内应留意泪液增加、季节性过敏等眼部症状。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To identify and characterize ocular adverse events (oAEs) that are significantly associated with proprotein convertase subtilisin-like/kexin type 9 (PCSK9) inhibitors using the US Food and Drug Administration Adverse Event Reporting System (FAERS). METHODS: We conducted a disproportionality analysis of PCSK9 inhibitors in the FAERS (01/2004-12/2021). The association between PCSK9 inhibitors and oAEs was evaluated using the information component (IC) and the reporting odds ratio (ROR), and the difference in oAEs between evolocumab and alirocumab was compared using the ROR. Different sensitivity analyses were conducted to evaluate the robustness of results. RESULTS: A total of 103 531 reports involving at least 1 PCSK9 inhibitor were found in the FAERS. PCSK9 inhibitors were associated with higher reporting of increased lacrimation (IC 0.27 [95% confidence interval {CI} 0.02-0.45]; ROR 1.21 [95% CI 1.04-1.40]), seasonal allergy (IC 0.39 [95% CI 0.04-0.64]; ROR 1.32 [95% CI 1.07-1.62]) and eye operation (IC 0.66 [95% CI 0.04-1.10]; ROR 1.60 [95% CI 1.11-2.30]) compared with the full database, and there was no difference between evolocumab and alirocumab. Sensitivity analyses showed that the disproportionate signals of increased lacrimation disappeared after excluding cases with other lipid-lowering agents in the combined drugs. Except for eye operations, most of these adverse events occurred within 30 days of the first dose, and all 3 oAEs were mostly reported in women and individuals >65 years. CONCLUSION: This pharmacovigilance study identified a possible signal of ocular disorders associated with PCSK9 inhibitors and encourages paying attention to at-risk populations in PCSK9 inhibitors medication.
引用
- Zhao X, Wu J, Zhu S, et al. Ocular disorders associated with PCSK9 inhibitors: A pharmacovigilance disproportionality analysis. Br J Clin Pharmacol. 2022. PMID: 35973681. doi:10.1111/bcp.15494
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。